518 completed. 518 Phase 1, 95 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 518 | Completed 518 |
| Phase 2 | 95 | Completed 95 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants MWN109 Tablets - Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity | Phase 1 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 162 | 2026-05-24 | 2026-09-03 |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight Cagrilintide B, Cagrilintide D - Overweight, Obesity | Phase 1 | Completed | Novo Nordisk A/S | 50 | 2026-05-20 | 2026-09-04 |
| A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants AZD5004, Mitiglinide, Pioglitazone - Healthy Participants | Phase 1 | Completed | AstraZeneca | 32 | 2026-03-13 | 2026-07-13 |
| A Food-Effect Study of CX11 in Healthy Participants CX11 (VCT220) - Obesity & Overweight, Type 2 Diabetes | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 32 | 2026-03-04 | 2026-10-13 |
| A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Completed | Boehringer Ingelheim | 56 | 2026-03-03 | 2026-06-15 |
| A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity PF-08653944 - Overweight, Obesity | Phase 1 | Completed | Pfizer | 48 | 2026-02-04 | 2026-08-17 |
| A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults SYNT101, Placebo - Healthy, Overweight and Obese Adults | Phase 1 | Completed | Syntis Bio | 55 | 2026-01-13 | 2026-08-26 |
| Bioequivalence Study of BGM0504 Injection BGM0504 Injection multi-dose pen, BGM0504 Injection single-dose pen - Overweight/Obesity | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 144 | 2025-12-29 | 2026-10-16 |
| A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients VCT220 - Obesity & Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 16 | 2025-12-25 | 2026-03-27 |
| Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations Petrelintide - Obesity & Overweight | Phase 1 | Completed | Zealand Pharma | 48 | 2025-12-17 | 2026-04-08 |
| A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight KAI-7535 - Obesity, Overweight | Phase 1 | Completed | Kailera | 18 | 2025-12-15 | 2026-01-29 |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations Maridebart Cafraglutide - Overweight and Obesity | Phase 1 | Completed | Amgen | 349 | 2025-12-15 | 2026-08-07 |
| A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic Acids NKS-3 and NKS-5 NKS-3, NKS-5 - Obesity & Overweight, Overweight (BMI > 30) | Phase 1 | Completed | EktaH | 120 | 2025-12-10 | 2026-11-09 |
| A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects HRS-7535 Tablets, Paracetamol Tablets, Digoxin Tablets - Obesity, Overweight | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 40 | 2025-12-07 | 2026-06-29 |
| A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants BGM1812, Placebo - Overweight or Obesity | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 60 | 2025-12-05 | 2026-10-15 |
| A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity CRB-913, Placebo - Obese But Otherwise Healthy Participants | Phase 1 | Completed | Corbus Pharmaceuticals Inc. | 254 | 2025-12-04 | 2026-10-09 |
| A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration) - Healthy Participants | Phase 1 | Completed | AstraZeneca | 19 | 2025-11-11 | 2026-10-15 |
| A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity LY3549492 - Healthy, Obesity | Phase 1 | Completed | Eli Lilly and Company | 120 | 2025-10-27 | 2026-11-09 |
| A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects BGM0504 tablets, Placebo tablets - Healthy, Non-diabetic Overweight or Obese | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 75 | 2025-10-24 | 2026-10-13 |
| Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants BMF-650 - Obesity | Phase 1 | Completed | Biomea Fusion Inc. | 90 | 2025-10-23 | 2026-10-27 |
Showing 20 of 518. Sign in to see all of them.
Obesity (469) · Diabetes Mellitus, Type 2 (55) · Diabetes Mellitus (27) · Weight Loss (26) · Nutrition Disorders (22) · Insulin Resistance (20) · Motor Activity (18) · Metabolic Syndrome (15) · Non-alcoholic Fatty Liver Disease (15) · Hypertension (14) · Cardiovascular Diseases (12) · Body Weight (10) · Obesity, Morbid (10) · Metabolic Diseases (9)
Nutritional and Metabolic Diseases (517) · Overnutrition (516) · Pathological Conditions, Signs and Symptoms (512) · Signs and Symptoms (509) · Body Weight (499) · Nutrition Disorders (496) · Glucose Metabolism Disorders (103) · Metabolic Diseases (102) · Endocrine System Diseases (76) · Diabetes Mellitus (49) · Behavior (31) · Body Weight Changes (30) · Hyperinsulinism (30) · Digestive System Diseases (22)
semaglutide (16) · Liraglutide (11) · Acetaminophen (10) · Sodium Chloride (10) · Metformin (9) · Rosuvastatin Calcium (9) · Tirzepatide (8) · BI 456906 (7) · Exercise (7) · Midazolam (6) · orforglipron (6) · cagrilintide (5) · lorcaserin (5) · ALT-801 (4) · Atorvastatin (4)
Novo Nordisk A/S (57) · Eli Lilly and Company (26) · Pfizer (20) · AstraZeneca (17) · Amgen (12) · Mayo Clinic (11) · Boehringer Ingelheim (10) · GlaxoSmithKline (9) · BrightGene Bio-Medical Technology Co., Ltd. (8) · University of Pittsburgh (8) · Vanderbilt University Medical Center (8) · Stanford University (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Vincentage Pharma Co., Ltd (5) · Altimmune, Inc. (4)
United States (298) · China (56) · Germany (31) · United Kingdom (22) · Australia (16) · Canada (15) · France (9) · Japan (7) · South Korea (7) · Denmark (6) · Brazil (4) · Singapore (4) · Austria (3) · Israel (3) · Netherlands (3)
Jack A Yanovski, M.D. (4) · John M Jakicic, Ph.D. (4) · Cyndya Shibao, MD (3) · Liyuan Zhao, Ph.D (3) · Wei Hu, Doctor (3) · Bonnie J Brehm, PhD (2)
PMID 12150647, PMID 36524539, PMID 36690550, PMID 41747885, PMID 12679447, PMID 15598683, PMID 15671108, PMID 15681386, PMID 16818482, PMID 16864756, PMID 17065354, PMID 17116758, PMID 18310192, PMID 18316660, PMID 18635428, PMID 18825363, PMID 18957534, PMID 19433800, PMID 19698154, PMID 19796996, PMID 19816674, PMID 19934630, PMID 20194883, PMID 20214807, PMID 20457158, PMID 20528109, PMID 20725058, PMID 20810979, PMID 20881066, PMID 21169160, PMID 21190985, PMID 21229331, PMID 21233083, PMID 21779093, PMID 21820871, PMID 21834938, PMID 21865361, PMID 21871113, PMID 21930881, PMID 21940598, PMID 22140269, PMID 22186428, PMID 22190676, PMID 22282429, PMID 22331684, PMID 22469621, PMID 22743313, PMID 22768902, PMID 22871173, PMID 23063681
2019 (5), 2023 (5), 2014 (3), 2009 (2), 2018 (2), K23HL103976 (2), K24DK059492 (2), R01DK091748 (2), 2008 (1), 2017 (1), K23DK114460 (1), K23GM100273 (1), K23HL085405 (1), P01AT002034 (1), P01HD030367 (1)